METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

摘要

The invention features pharmaceutical compositions, kits, and methods for treating a subject diagnosed with, or at risk of developing cancer, by administering a mammalian target of rapamycin (mTOR) inhibitor, an mTOR reducing agent, or an mTOR signaling inhibitor, and one or more agents selected from the group of: an insulin growth factor- 1 receptor (IGFIR) inhibitor, an IGFIR reducing agent, an IGFIR signaling inhibitor, a B-cell CLL/lymphoma 2 (bcl-2) inhibitor, a bcl-2 reducing agent, a sarcoma (src) inhibitor, a src reducing agent, a src signaling inhibitor, a ribosomal S6 kinase (rsk) inhibitor, a rsk reducing agent, a rsk signaling inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, an EGFR reducing agent, an EGFR signaling inhibitor, a focal adhesion kinase (FAK) inhibitor, a FAK reducing agent, a FAK signaling inhibitor, a vascular endothelial growth factor (VEGF) inhibitor, a VEGF reducing agent, a VEGF signaling inhibitor, a PERK inhibitor, or a PERK reducing agent. The invention also provides methods for identifying a cancer in a subject requiring the steps of measuring the expression level or biological activity of mTOR or PI3K in a sample from the subject and measuring the expression level or biological activity of one or more of IGFIR, B-bcl-2, src, rsk, FAK, VEGF, and PERK in the sample; where a decrease in the expression level or biological activity of mTOR or PI3K, and an increase in the expression level or biological activity of one or more of IGFIR, bcl-2, src, rsk, FAK, VEGF, and PERK identifies a cancer in the subject.